Global COPD & Asthma Devices Market By Product Type (COPD & Asthma Inhaler - Dry Powder Inhalers, Metered Dose Inhalers, Soft Mist Inhalers; COPD & Asthma Nebulizer - Pneumatic Nebulizers, Ultrasonic Nebulizer, Mesh Nebulizer)
Special Offering :
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
The global asthma and COPD drug market is a multi-billion dollar market which has a history of several decades and has witnessed number of technological advancements and product development over the past few years. Growing aging population coupled with increasing automotive and industrial exhaust gases have remained the key drivers for the global asthma and COPD market. Degrading air quality near the industrial areas has led to the increased incidence of asthma especially in the low-income population in the emerging economies of China, India, Brazil and Russia. Increasing disposable income levels in emerging economies as well as developing countries of Latin America, Middle East & Africa has led to the increased usage of asthma pumps and sprays in these regions. However, the unknown etiology of asthma and COPD in medical industry may hamper the market growth in the next six years.
Upcoming treatment methodologies such as once-a-day combination products and monoclonal antibodies have created new opportunities for the market growth. Additionally, pharmaceutical companies have been developing new bio-based medications in combination with bio-technology which promises immense growth opportunities along with sustainable development for asthma & COPD market over the next decade. The report highlights the adoption of COPD & Asthma Devices worldwide. Based on the product type; the market is segmented into Inhalers and Nebulizers market. Further the Inhaler segment is sub segmented into Dry Powder Inhalers, Metered Dose Inhalers and Soft Mist Inhalers Market. The Nebulizers segment is bifurcated into Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers Market.
The geographies included in the report are North America, Europe, Asia Pacific and LAMEA (Latin America, Middle East and Africa). Key players profiled in the report include Glaxosmithcline PLC., Novartis International AG., Biotronik SE & Co. KG., AstraZeneca Plc., 3M Healthcare, GF Health Products, Inc., Sunovion Pharmaceuticals Inc., Smith Medicals, Inc., Baxter International and Philips.